FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry
Executive Summary
The biotech industry faces a tightrope challenge in commenting on FDA's draft guidance on assay development for immunogenicity testing of therapeutic proteins. Companies want clarity from the agency, as well as limits to the scope of the guidelines. But firms also want to make sure that however the lines are drawn, follow-on biologics have strict testing requirements
You may also be interested in...
Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration
A research collaboration agreement between FDA and Northeastern University could help agency officials understand the mechanisms of action of follow-on biologics, thus easing the way for these products once Congress establishes an approval pathway
Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration
A research collaboration agreement between FDA and Northeastern University could help agency officials understand the mechanisms of action of follow-on biologics, thus easing the way for these products once Congress establishes an approval pathway
FDA Biosimilars Program Gets Seed Money In Administration's FY '11 Budget
FDA plans to spend $5.7 million in fiscal 2011 to develop drug review standards and make other preparations for an approval pathway for follow-on biologics